trending Market Intelligence /marketintelligence/en/news-insights/trending/gjgU_7tgenSyRlo0nAmPKQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Chiasma resubmits application for hormonal disorder drug in US

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Chiasma resubmits application for hormonal disorder drug in US

Chiasma Inc. said it resubmitted a new drug application for Mycapssa in the U.S.

The Waltham, Mass.-based biopharmaceutical company is seeking the U.S. Food and Drug Administration's approval to market Mycapssa as a maintenance treatment for adults with acromegaly, a hormonal disorder that causes an increase in the size of bones of the hands, feet and face. Maintenance therapy is an add-on treatment meant to bolster the main therapy.

Chiasma said in a Jan. 10 press release that its application was backed by positive data from a phase 3 trial, dubbed Chiasma Optimal.

The company said it expects a six-month review of the filing and expects a decision by the FDA by mid-year and hopes to bring the product to the market during the fourth quarter of 2020.

Chiasma also expects to report results from an international phase 3 trial of Mycapssa — called Mpowered — to support the drug's approval in the EU.